Mary Kathleen Flynn
'Buyers don't have the time or resources to compete in a drawn-out auction process, instead finding themselves willing to pay a steeper multiple to ensure they will win the asset and take it off the table extremely quickly,' explains Robert Reifman, managing director, Lincoln International.
EQT sold Aldevron for $9.6bn just 22 months after buying the maker of mRNA vaccine components for $3.4bn.

